Pfizer strikes deal with Sangamo, broadening hemophilia pipeline

NEW YORK (Reuters) - U.S. drugmaker Pfizer Inc said on Wednesday it reached an agreement with Sangamo Therapeutics Inc for rights to its gene therapy programs to treat the rare blood-clotting disorder hemophilia A, under which Pfizer will pay $70 million upfront.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news